Rafestin-Oblin ME - Search Results

1

Mineralocorticoid receptor mutations differentially affect individual gene expression profiles in pseudohypoaldosteronism type 1.

Fernandes-Rosa FL, Hubert EL, Fagart J, Tchitchek N, Gomes D, Jouanno E, Benecke A, Rafestin-Oblin ME, Jeunemaitre X, Antonini SR, Zennaro MC. Fernandes-Rosa FL, et al. Among authors: rafestin oblin me. J Clin Endocrinol Metab. 2011 Mar;96(3):E519-27. doi: 10.1210/jc.2010-1486. Epub 2010 Dec 15. J Clin Endocrinol Metab. 2011. PMID: 21159846

2

Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1.

Hubert EL, Teissier R, Fernandes-Rosa FL, Fay M, Rafestin-Oblin ME, Jeunemaitre X, Metz C, Escoubet B, Zennaro MC. Hubert EL, et al. Among authors: rafestin oblin me. J Am Soc Nephrol. 2011 Nov;22(11):1997-2003. doi: 10.1681/ASN.2011030245. Epub 2011 Sep 8. J Am Soc Nephrol. 2011. PMID: 21903996 Free PMC article.

3

The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related.

Rafestin-Oblin ME, Souque A, Bocchi B, Pinon G, Fagart J, Vandewalle A. Rafestin-Oblin ME, et al. Endocrinology. 2003 Feb;144(2):528-33. doi: 10.1210/en.2002-220708. Endocrinology. 2003. PMID: 12538613

4

Structural determinants of ligand binding to the mineralocorticoid receptor.

Huyet J, Pinon GM, Fay MR, Rafestin-Oblin ME, Fagart J. Huyet J, et al. Among authors: rafestin oblin me. Mol Cell Endocrinol. 2012 Mar 24;350(2):187-95. doi: 10.1016/j.mce.2011.07.035. Epub 2011 Jul 25. Mol Cell Endocrinol. 2012. PMID: 21820032 Review.

5

Structural basis of spirolactone recognition by the mineralocorticoid receptor.

Huyet J, Pinon GM, Fay MR, Fagart J, Rafestin-Oblin ME. Huyet J, et al. Mol Pharmacol. 2007 Sep;72(3):563-71. doi: 10.1124/mol.107.036459. Epub 2007 Jun 14. Mol Pharmacol. 2007. PMID: 17569793

6

Glucocorticoid metabolism by 11-beta hydroxysteroid dehydrogenase type 2 modulates human mineralocorticoid receptor transactivation activity.

Bocchi B, Fagart J, Cluzeaud F, Fay M, Rafestin-Oblin ME, Farman N. Bocchi B, et al. J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):239-44. doi: 10.1016/s0960-0760(03)00036-0. J Steroid Biochem Mol Biol. 2003. PMID: 12711009

7

The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor.

Fagart J, Seguin C, Pinon GM, Rafestin-Oblin ME. Fagart J, et al. Mol Pharmacol. 2005 May;67(5):1714-22. doi: 10.1124/mol.104.010710. Epub 2005 Feb 16. Mol Pharmacol. 2005. PMID: 15716462

8

11beta-hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells.

Rafestin-Oblin ME, Fagart J, Souque A, Seguin C, Bens M, Vandewalle A. Rafestin-Oblin ME, et al. Mol Pharmacol. 2002 Dec;62(6):1306-13. doi: 10.1124/mol.62.6.1306. Mol Pharmacol. 2002. PMID: 12435797

9

Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension.

Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, Rafestin-Oblin ME. Fagart J, et al. Nat Struct Mol Biol. 2005 Jun;12(6):554-5. doi: 10.1038/nsmb939. Epub 2005 May 22. Nat Struct Mol Biol. 2005. PMID: 15908963

10

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.

Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, Khan JA, Hillisch A, Lombès M, Rafestin-Oblin ME, Fagart J. Amazit L, et al. Among authors: rafestin oblin me. J Biol Chem. 2015 Sep 4;290(36):21876-89. doi: 10.1074/jbc.M115.657957. Epub 2015 Jul 22. J Biol Chem. 2015. PMID: 26203193 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page